UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

A First Time in Human, Microdose, Positron Emission Tomography Study of the Safety, Immunogenicity, Biodistribution and Radiation Dosimetry of [18F]FB-A20FMDV2 for Imaging the Integrin αvβ6

Keat, N; Kenny, J; Chen, K; Onega, M; Garman, N; Slack, R; Parker, C; ... Lukey, P; + view all (2018) A First Time in Human, Microdose, Positron Emission Tomography Study of the Safety, Immunogenicity, Biodistribution and Radiation Dosimetry of [18F]FB-A20FMDV2 for Imaging the Integrin αvβ6. Journal of Nuclear Medicine Technology , 40 (2) pp. 136-143. 10.2967/jnmt.117.203547. Green open access

[thumbnail of Lumbers_avb6 dosimetry paper FINAL1.pdf]
Preview
Text
Lumbers_avb6 dosimetry paper FINAL1.pdf - Accepted Version

Download (1MB) | Preview

Abstract

The αvβ6 integrin is involved in the pathogenesis of cancer and fibrosis. A radiolabeled 20-amino-acid αvβ6-binding peptide, derived from the foot and mouth virus (NAVPNLRGDLQVLAQKVART [A20FMDV2]), has been developed to image αvβ6 levels preclinically. This study was designed to translate these findings into a clinical PET imaging protocol to measure the expression of αvβ6 in humans. Methods: Preclinical toxicology was undertaken, and a direct immunoassay was developed for 4-fluorobenzamide (FB)-A20FMDV2. Four healthy human subjects (2 male and 2 female) received a single microdose of 18F-FB-A20FMDV2 followed by a multibed PET scan of the whole body over more than 3 h. Results: There were no findings in the preclinical toxicology assessments, and no anti-A20FMDV2 antibodies were detected before or after dosing with the PET ligand. The mean and SD of the administered mass of 18F-FB-A20FMDV2 was 8.7 ± 4.4 μg (range, 2.7–13.0 μg). The mean administered activity was 124 ± 20 MBq (range, 98–145 MBq). There were no adverse or clinically detectable pharmacologic effects in any of the subjects. No significant changes in vital signs, laboratory study results, or electrocardiography results were observed. Uptake of radioactivity was observed in the thyroid, salivary glands, liver, stomach wall, spleen, kidneys, ureters, and bladder. Time–activity curves indicated that the highest activity was in the bladder content, followed by the kidneys, small intestine, stomach, liver, spleen, thyroid, and gallbladder. The largest component of the residence times was the voided urine, followed by muscle, bladder, and liver. Using the mean residence time over all subjects as input to OLINDA/EXM, the effective dose was determined to be 0.0217 mSv/MBq; using residence times from single subjects gave an SD of 0.0020 mSv/MBq from the mean. The critical organ was the urinary bladder, with an absorbed dose of 0.18 mGy/MBq. Conclusion: 18F-FB-A20FMDV2 successfully passed toxicology criteria, showed no adverse effects in this first-in-humans study, and has an effective dose that enables multiple scans in a single subject.

Type: Article
Title: A First Time in Human, Microdose, Positron Emission Tomography Study of the Safety, Immunogenicity, Biodistribution and Radiation Dosimetry of [18F]FB-A20FMDV2 for Imaging the Integrin αvβ6
Open access status: An open access version is available from UCL Discovery
DOI: 10.2967/jnmt.117.203547
Publisher version: https://doi.org/10.2967/jnmt.117.203547
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: FTiH, PET, αvβ6, integrin, A20FMDV2
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Health Informatics
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Health Informatics > Infectious Disease Informatics
URI: https://discovery.ucl.ac.uk/id/eprint/10058273
Downloads since deposit
91Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item